Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Paclitaxel (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 23 Mar 2017 New trial record